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was achieved using medical records and/or phone calls and was censored at 2 years.
Descriptive analysis was performed on all variables. Univariate analysis and propensity
matched analysis were performed to determine differences between the 2 cohorts.
Results: E had more hypertension and a higher angiographic complexity than Y patients
as judged by SYNTAX scoring (E 22.4  14.2; Y 17.5  12.5, p  0.026). A higher
prevalence of smoking, obesity and family history of premature heart disease was seen in
Y patients. At 2 years follow up, Y vs. E patients had the following outcomes respectively:
TLF 27.7% and 25.5% (p0.711), TLR (24.8% vs. 21.4%, p0.518), cardiac death
(3.4% vs. 2.5%, p0.750) and definite and probable stent thrombosis (2.0% vs. 1.0%).
Propensity matched analysis showed a statistically similar TLF and TVF between the Y
and E cohorts respectively (31.3% vs. 21.9% (p0.317) and 46.2% vs. 32.3% (p0.150)
respectively). The EES had lower TLR than PES in the E (15.7% vs. 27.7%, p0.055)
but similar outcomes between the 2 stents were seen in the Y cohort.
Conclusion: In this cohort of patients receiving EES and PES, and when compared to
young patients ( 65 years), elderly patients ( 65 years) had more complex angiographic
disease but statistically similar outcomes at 2- year follow-up. EES appears to have lower
TLR in elderly patients than PES.
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Background: To evaluate the safety and effectiveness of the Elixir DESyneTM BD
Novolimus Eluting Coronary Stent System (CSS) with a bioabsorbable polymer com-
pared to the Endeavor Zotarolimus Eluting Coronary Stent System through the
assessment of clinical, angiographic, and IVUS endpoints.
Method: 149 patients were randomized 3:1, either to the Elixir DESyne BD Novolimus
Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus
metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the Endeavor
Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of Zotarolimus
eluted via a durable phosphoryl choline polymer. All patients were analyzed for the
primary endpoint of in-stent late lumen loss (LLL) assessed by QCA at 6 months.
Moreover, all patients underwent evaluation for the secondary endpoints including the
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis
at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for
angiographic endpoints at 6 months including: in-segment LLL, percent diameter
stenosis, minimal lumen diameter post-procedure and at 6 months, and angiographic
binary restenosis (ABR) (50%). A subset of patients underwent intravascular ultrasound
(IVUS) evaluation including percent (%) neointimal obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs
7.9%, p0.003). Excellent clinical results at 6 months were demonstrated for both
devices. Clinical results through 12 months and additional angiographic and IVUS results
will be presented.
Conclusion: Clinical results through 12 months and complete angiographic and IVUS
results will be presented.
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Background: Chronic total occlusion (CTO) intervention is still challenging because of
the limited procedural success rate and higher recurrence. It is not clear whether the
peri-procedural myocardial infarction (P-MI) will significantly impact on angiographic
and clinical outcomes following CTO intervention.
Methods: A total of 131 consecutive pts underwent CTO intervention were divided into
P-MI (n12) and control group (n119). Six-month angiographic and twelve-month
clinical outcomes were compared between the two groups.
Results: The baseline clinical characteristics were balanced between the two groups
except more elderly (66.113.0 vs. 60.19.4 p0.034) in the P-MI group. There were
higher incidence of perforation (15.3% vs. 0.7%, p0.0005), dissection (46.1% vs.18.1%,
p0.018), any hematoma and acute renal failure in the P-MI group. Angiographic
outcomes at 6 months were not different between the two groups. However, the incidence
of total death, any myocardial infarction (MI) and target vessel revascularization
(TVR)-major adverse cardiac events (MACE) were higher in the P-MI group at 24
months (Table).
Conclusions: P-MI following CTO intervention was associated with higher 2-year
mortality, any MI and TVR-MACE. Careful procedure to minimize P-MI will be
warranted to get optimal CTO intervention outcomes.
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Aims: To evaluate safety and effectiveness of the Elixir DESyneTM Novolimus-Eluting
Coronary Stent System (CSS) compared to the Endeavor Zotarolimus-Eluting CSS
through assessment of clinical, angiographic, and IVUS endpoints.
Method and Results: 210 patients were randomized 2:1 either to the DESyne CSS
loaded with 5mcg per mm of stent length of Novolimus, a sirolimus metabolite, eluted via
a durable methacrylate polymer, or to the Endeavor CSS loaded with 10mcg per mm of
stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients
were analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA at 9
months. All patients also underwent evaluation for secondary endpoints which included a
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent
thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents were
also assessed for angiographic endpoints at 9 months including: in-stent and in-segment LLL.
A subset of patients underwent IVUS evaluation including percent neointimal obstruction at
9 months. The study met the non-inferiority endpoint and also demonstrated superiority of the
DESyne CSS as compared to control for in-stent LLL (0.110.32 vs. 0.630.42, p 0.001).
Clinical results through 2 years trend lower for the DESyne stent (4.3% vs, 9.0%, p0.14)
driven primarily by increased TLR fro the Endeavor.
Conclusions: The study met the non-inferiority endpoint and also demonstrated
superiority of the DESyne CSS as compared to control. Clinical results through 3 years
and a review of angiographic and IVUS results will be presented.
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Background: Contrast induced nephropathy (CIN) is an increasing problem in
cardiology invasive imaging, limited by the absence of treatment and few prevention
methods. Anti oxidant benefits of ascorbic acid have been reported by small series but
evidence remains poor.
Aim: To evaluate the effect of ascorbic acid administration in CIN occurrence in patients
undergoing coronarography.
Methods: Patients undergoing coronarography between March and November 2010
were prospectively and blindly randomized to control group receiving a standard CIN
prevention protocol including saline hydration and ascorbic acid group receiving saline
hydration with ascorbic acid (3g 2hours before the procedure then 2g the day after and
next day). We excluded patients requiring hemodialysis, those with acute renal insuffi-
ciency, heart failure with LVEF  40%, digestive resections, and previous contrast
medium injection and aspirin or ascorbic acid intake. Endpoint was occurrence of CIN
defined as a 25% raise of creatinine level 48 to 72 h after coronarography.
Results: Two hundred two patients were included, 95 in control group and 107 in
ascorbic acid group. Mean age was 66 years and 60% were men. Baseline characteristics
were similar between the two groups. Creatinin level before intervention was 98.6  29
mol/l and contrast medium administrated was 71.6  25 ml. CIN occurred in 31
(15.3%) patients. It was significantly lower in ascorbic acid group (10.3% vs 21.1%,
p0.03).
Conclusion: Ascorbic acid showed to reduce CIN incidence in patients undergoing
coronarography compared with saline hydration alone.
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Background: Contrast-induced nephropathy (CIN) is a frequent complication after
coronary angiography. In the exclusion of saline hydration, the effectiveness of other
means of prevention remains unclear, and almost poor. Thanks to its pleotropic effects,
statins have been used in CIN prevention, but data remains controversial.
Objective: To evaluate the benefit of statins in the prevention of CIN after coronary
angiography.
Methods: We used the database of a randomized controlled trial conducted in the
Cardiology B department of Monastir’s Hospital during the period March to
November 2010 to study the effectiveness of ascorbic acid in the prevention of
CIN. Patients undergoing coronary angiography were randomly assigned to a
saline hydration prevention protocol or a saline hydration associated to ascorbic
acid protocol. The primary endpoint was the occurrence of CIN defined as a
creatinin arise of more than 25% the baseline level during the following 48 to 72
hours. The relationship between statin intake at baseline and CIN incidence was
retrospectively evaluated using a Chi-square test.
Results: Among the 202 patients included, 126 (62.3%) were treated with statins. There
was no significant difference between the two groups concerning the baseline character-
istics, particularly in ascorbic acid treatment (p0.94). CIN incidence dropped from
20.8% in the patients not taking statins to 11.7% in those treated with statins. This
resulted in a tendency (p0.08) but difference wasn’t statistically significant, probably due
to the small sample of the population.
Conclusion: In our study, treatment with statins led to a trend to reduce CIN incidence.
The small sample of the population couldn’t allow stronger conclusion. Statins seem to be
promising but larger trials are needed.
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Background: The long term safety and efficacy of 1st and 2nd generation drug eluting
stents (DES) is of continued clinical importance. We aimed at exploring the potential
differences in clinical outcomes between various DES types.
Methods and Results: We followed 9,584 consecutive patients undergoing PCI at our
institution (years 2004-2012, mean f/u duration 4 years). Patients treated with bare metal
stents 5,599 (58.4%) were compared to 3,985 (41.5%) DES counterparts. The sirolimus
eluting stent (SES) was taken as the prototype DES and compared to other DESs (e.g.
Paclitaxel [P], Zotarolimus-Endeavor [ZE], Zotarolinus-Resolute [ZR], Everolimus [E]
and Biolimus [B] ESs), using propensity matching. Primary outcome was the rate of
composite endpoint of total mortality, MI, clinically driven TVR/CABG. At 3 years, the
composite end point was significantly lower in the DES vs. BMS group (20.0% vs. 26.4%;
P0.001). The comparisons between SES with each one of the 5 other DESs, were very
well balanced and did not yield significant differences for the 3 year primary composite
endpoint: SES vs. PES (n350 pairs; 18.1% vs. 17.7% pNS), SES vs. ZEES (n474
pairs : 21.8% vs. 23.2%, pNS), SES vs. ZRES (n434 pairs; 16.9% vs. 11.7% pNS),
SES vs. EES (n824 pairs; 14.2% vs. 14.1%, pNS) and SES vs. BES (n117 pairs;
13.7% vs. 13.4%, pNS).
Conclusions: We found: 1) no differences in the cardiac prognosis between SES and
other DESs, 2) the use of DES was associated with better clinical outcomes compared to
BMS.
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Purpose: Evaluate the effect of invasive (IT) and non-invasive treatment (NIT)
modalities on hospitalization cost and readmission rate in patients admitted with cocaine
induced chest pain (CICP).
Introduction: As cocaine use has become more widespread, the number of cocaine-
related cardiovascular events and cost of care has increased. A high percentage of patients
with cocaine associated chest discomfort are admitted to the hospital, with an average stay
of three days. A 9-12 hours observation in a chest pain unit has been validated to be safe
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